Access Industries-backed Acelyrin filed to go public while Lockheed Martin took part in Orbit Fab’s $28.5m series A round.

Close-up Photo of Monitor

Public markets

Acelyrin, a US-based inflammatory disorder drug developer backed by industrial conglomerate Access Industries, filed to raise $100m in an initial public offering on the Nasdaq Global Market. It has received a total of $408m in venture funding, and the corporate’s Access Biotechnology unit owns a 3.9% stake having led a $300m series C round in September 2022.

CytoMed Therapeutics, a Singapore-based cancer…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in